$STEK
Stemtech Corp Stock $stek

$stek Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023772 Filed on August 23, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$1.047M	$1.276M	$1.313M
YoY Change	15.33%	24.52%
Cost Of Revenue	$180.6K	$393.2K	$447.4K
YoY Change	42.85%	46.09%
Gross Profit	$866.4K	$883.2K	$865.1K
YoY Change	10.88%	16.83%
Gross Profit Margin	82.75%	69.19%	65.91%
Selling, General & Admin	$3.943M	$1.618M	$2.047M
YoY Change	184.93%	35.79%	93354.79%
% of Gross Profit	455.04%	183.23%	236.58%
Research & Development	$0.00	$0.00
YoY Change
% of Gross Profit	0.0%	0.0%
Depreciation & Amortization	$113.5K	$109.6K	$104.4K
YoY Change	-65.01%
% of Gross Profit	13.09%	12.41%	12.06%
Operating Expenses	$4.249M	$1.911M	$2.686M
YoY Change	180.05%	43.27%	122562.56%
Operating Profit	-$3.382M	-$1.028M	-$1.821M
YoY Change	359.72%	77.82%
Interest Expense	$16.40M	-$23.18M	$1.058M
YoY Change	-455.46%	10315.69%	-26753.15%
% of Operating Profit
Other Income/Expense, Net	$20.77M	-$23.94M	-$85.08K
YoY Change	72823.58%	12176.33%
Pretax Income	$17.39M	-$24.97M	-$848.2K
YoY Change	-426.83%	3129.07%	13668.83%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	$17.42M	-$24.95M	-$839.5K
YoY Change	-428.04%	3171.62%	13528.41%
Net Earnings / Revenue	1663.46%	-1954.54%	-63.96%
Basic Earnings Per Share	$0.38	-$0.56
Diluted Earnings Per Share	$0.38	-$0.56	-$34.47K
COMMON SHARES
Basic Shares Outstanding	44.80M shares	44.71M shares
Diluted Shares Outstanding	45.59M shares	44.71M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.1K	$399.7K	$828.2K
YoY Change	-92.3%	81477.55%	37375.57%
Cash & Equivalents	$123.1K	$399.7K	$828.2K
Short-Term Investments
Other Short-Term Assets	$255.1K	$220.5K	$324.7K
YoY Change	-31.46%	91.57%	341.96%
Inventory	$181.8K	$201.1K	$436.4K
Prepaid Expenses
Receivables	$39.75K	$24.07K	$10.72K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$599.7K	$845.4K	$1.600M
YoY Change	-71.99%	631.35%	2014.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.70K	$30.67K	$33.17K
YoY Change	-71.09%
Goodwill	$467.4K	$467.4K	$467.4K
YoY Change
Intangibles	$3.097M	$3.200M	$3.407M
YoY Change
Long-Term Investments	$28.42K	$29.03K	$38.69K
YoY Change	-35.47%
Other Assets
YoY Change
Total Long-Term Assets	$3.751M	$3.873M	$4.120M
YoY Change	-9.29%
TOTAL ASSETS
Total Short-Term Assets	$599.7K	$845.4K	$1.600M
Total Long-Term Assets	$3.751M	$3.873M	$4.120M
Total Assets	$4.351M	$4.719M	$5.720M
YoY Change	-30.68%	3982.11%	7459.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.868M	$3.866M	$4.051M
YoY Change	40.99%	108793.8%
Accrued Expenses	$62.02K	$65.36K	$55.75K
YoY Change	-86.95%
Deferred Revenue
YoY Change
Short-Term Debt	$1.631M	$1.787M	$1.056M
YoY Change	148.15%	396.47%	255.48%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.995M	$33.33M	$9.387M
YoY Change	39.2%	9068.7%	2951.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$77.64K	$219.5K
YoY Change	-100.0%
Other Long-Term Liabilities	$71.55K	$82.62K	$119.1K
YoY Change	-98.2%
Total Long-Term Liabilities	$71.55K	$160.3K	$338.5K
YoY Change	-98.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.995M	$33.33M	$9.387M
Total Long-Term Liabilities	$71.55K	$160.3K	$338.5K
Total Liabilities	$9.067M	$33.49M	$9.726M
YoY Change	-9.95%	9112.79%	3061.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.11M	-$38.50M	-$13.09M
YoY Change
Common Stock	$48.63K	$10.71M	$10.16M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.001M	-$28.09M	-$3.356M
YoY Change
Total Liabilities & Shareholders Equity	$4.351M	$4.719M	$5.720M
YoY Change	-30.68%	3982.11%	7459.3%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	$17.42M	-$24.95M	-$839.5K
YoY Change	-428.04%	3171.62%	13528.41%
Depreciation, Depletion And Amortization	$113.5K	$109.6K	$104.4K
YoY Change	-65.01%
Cash From Operating Activities	-$231.4K	-$663.8K	-$1.070M
YoY Change	-69.43%	1382.45%	3465.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			-$880.00
YoY Change
Cash From Investing Activities			-$880.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	361.1K	184.4K	524.3K
YoY Change	-82.12%	309.82%	1647.77%
NET CHANGE
Cash From Operating Activities	-231.4K	-663.8K	-1.070M
Cash From Investing Activities			-880.0
Cash From Financing Activities	361.1K	184.4K	524.3K
Net Change In Cash	129.7K	-479.4K	-547.0K
YoY Change	-89.73%	-218018.18%	2734650.0%
FREE CASH FLOW
Cash From Operating Activities	-$231.4K	-$663.8K	-$1.070M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021Q4	STEK	Factoring Liability FactoringLiability		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q2	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1		usd
	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	STEK	Stock Issued During Period Value Effect Of Recapitalization StockIssuedDuringPeriodValueEffectOfRecapitalization		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001511820
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	STEK	Stock Issued To Vendor For Services StockIssuedToVendorForServices		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	STEK	Gain Loss On Forgiveness Of Ppp Loan GainLossOnForgivenessOfPppLoan		usd
	STEK	Repayment Of Debt RepaymentOfDebt		usd
	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease		usd
CY2021Q4	STEK	Factoring Liability FactoringLiability		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-172172
	dei	Entity Registrant Name EntityRegistrantName	STEMTECH CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2151440
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10370 USA Today Way
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miramar
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33025
	dei	City Area Code CityAreaCode	(954)
	dei	Local Phone Number LocalPhoneNumber	715-6000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	STEK
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44795673	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	399729	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	828206	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	24072	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	10720	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	201127	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	436405	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	220517	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	324708	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	845445	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1600039	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30667	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33168	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3199521	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3406714	usd
CY2022Q2	us-gaap	Goodwill Goodwill	467409	usd
CY2021Q4	us-gaap	Goodwill Goodwill	467409	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	146847	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	174100	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	29027	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38692	usd
CY2022Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	3873471	usd
CY2021Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	4120083	usd
CY2022Q2	us-gaap	Assets Assets	4718916	usd
CY2021Q4	us-gaap	Assets Assets	5720122	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3865725	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4050798	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1569299	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1055910	usd
CY2022Q2	STEK	Factoring Liability FactoringLiability	217907	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65359	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55745	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	27612689	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4224585	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	33330979	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9387038	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	77642	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	219465	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	82617	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119065	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	160259	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	338530	usd
CY2022Q2	us-gaap	Liabilities Liabilities	33491238	usd
CY2021Q4	us-gaap	Liabilities Liabilities	9725568	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44795673	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44795673	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44685673	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44685673	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	44795	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	44685	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10663909	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10116296	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-267548	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-430255	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38529297	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13086318	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-28088141	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3355592	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-684181	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-649854	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28772322	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4718916	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5720122	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1276424	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1025112	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2432732	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2100873	usd
CY2022Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	382831	usd
CY2021Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	268878	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	629057	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	448760	usd
CY2022Q2	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	10382	usd
CY2021Q2	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	285	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	26753	usd
	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	548	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	393213	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	269163	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	655810	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	449308	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	883211	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	755949	usd
	us-gaap	Gross Profit GrossProfit	1776922	usd
	us-gaap	Gross Profit GrossProfit	1651565	usd
CY2022Q2	STEK	Commission Expenses CommissionExpenses	293140	usd
CY2021Q2	STEK	Commission Expenses CommissionExpenses	142452	usd
	STEK	Commission Expenses CommissionExpenses	455052	usd
	STEK	Commission Expenses CommissionExpenses	241582	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	139275	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	81355	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	279584	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	210960	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1478990	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1110358	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2251002	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1852326	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1911405	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	1334165	usd
	us-gaap	Operating Expenses OperatingExpenses	2985638	usd
	us-gaap	Operating Expenses OperatingExpenses	2304868	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1028194	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-578216	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1208716	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-653303	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-927	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-62647	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1951	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-67409	usd
CY2022Q2	us-gaap	Interest Expense Other InterestExpenseOther	645651	usd
CY2021Q2	us-gaap	Interest Expense Other InterestExpenseOther	132360	usd
	us-gaap	Interest Expense Other InterestExpenseOther	1171017	usd
	us-gaap	Interest Expense Other InterestExpenseOther	222590	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-22538626	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-22341116	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-878806	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-878806	usd
CY2022Q2	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	124300	usd
	STEK	Gains Losses On Extinguishment Of Debt1 GainsLossesOnExtinguishmentOfDebt1	124300	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23939710	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-195007	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24268590	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-289999	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24967904	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-773223	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25477306	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-943302	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-24967904	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-773223	usd
	us-gaap	Profit Loss ProfitLoss	-25477306	usd
	us-gaap	Profit Loss ProfitLoss	-943302	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-19665	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10658	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34327	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14735	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-24948239	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-762565	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25442979	usd
	us-gaap	Net Income Loss NetIncomeLoss	-928567	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44712562	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35684022	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44699117	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35311381	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44712562	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35684022	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44699117	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35311381	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-24948239	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-762565	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25442979	usd
	us-gaap	Net Income Loss NetIncomeLoss	-928567	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-367960	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-466980	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-162707	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-203483	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24580279	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-295585	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25280272	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-725084	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	896097	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	303678	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	466980	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10658	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-762565	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	893532	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1267996	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	365355	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	203483	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14735	usd
	us-gaap	Net Income Loss NetIncomeLoss	-928567	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	893532	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4611841	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	109463	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	30000	usd
CY2022Q2	STEK	Stock Issued During Period Value Of Loan Extension StockIssuedDuringPeriodValueOfLoanExtension	300000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	367960	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-19665	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-24948239	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28772322	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	217723	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	30000	usd
	STEK	Stock Issued During Period Value Of Loan Extension StockIssuedDuringPeriodValueOfLoanExtension	300000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	162707	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34327	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25442979	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28772322	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28772322	usd
	us-gaap	Profit Loss ProfitLoss	-25477306	usd
	us-gaap	Profit Loss ProfitLoss	-943302	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	216717	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	223986	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	217723	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	367004	usd
	STEK	Stock Issued To Vendor For Services StockIssuedToVendorForServices	-30000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1028375	usd
	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	27253	usd
	STEK	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	22928	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-22341116	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-878806	usd
	STEK	Gain Loss On Forgiveness Of Ppp Loan GainLossOnForgivenessOfPppLoan	124300	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13352	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13320	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-235278	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21378	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-104191	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	56707	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-192096	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	119499	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-9665	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	49833	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-26834	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22307	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-744764	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-346790	usd
	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	241000	usd
	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	176245	usd
	STEK	Repayment Of Debt RepaymentOfDebt	-88215	usd
	STEK	Repayment Of Note Payable And Factoring Liability RepaymentOfNotePayableAndFactoringLiability	175635	usd
	STEK	Repayment Of Note Payable And Factoring Liability RepaymentOfNotePayableAndFactoringLiability	58664	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	153580	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	117581	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	162707	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	203483	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-428477	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25726	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	828206	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	133065	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	399729	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	107339	usd
	STEK	Recognition Of Right Of Use Asset Operating Lease RecognitionOfRightOfUseAssetOperatingLease	53463	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80E_eus-gaap--NatureOfOperations_zODDFMGqBld7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_824_zr0lPiJZ1Uj4">Organization and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Corporation and its Subsidiaries (collectively, the “Company”) was incorporated in the State of Nevada, USA on September 4, 2009 under the previous name Globe Net Wireless Corp. On November 19<sup>th</sup>, 2021, the Company adopted an Amendment to its Articles changing the name of the Corporation to Stemtech Corporation in the state of Nevada, and on April 14<sup>th</sup>, 2022, FINRA gave final approval for said name change, as seen by the 8K filed that date. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes our products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our Mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Companies subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, OraStem® (Oral Health Care), and D-Fuze™ (Electromagnetic Frequency Blocker).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2021, Stemtech Corporation (“Stemtech”), a (Delaware corporation), entered into a Merger Agreement (the “Merger Agreement”) with Globe Net Wireless Corp. (“Globe Net” or “GNTW”). The merger was accounted for as a reverse acquisition and recapitalization in accordance with the Financial Accounting Standards Board (ASC 805, Business Combinations). Management evaluated the guidance contained in ASC 805 with respect to the identification of the acquirer in the merger and concluded, based on a consideration of the pertinent facts and circumstances, that Stemtech acquired Globe Net for financial accounting purposes. On November 9, 2021, the Company changed its fiscal year end date from August to December.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such consolidated financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. All intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements include the accounts of Stemtech Corporation (Parent) and its nine (9) subsidiaries:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech HealthSciences Corp (U.S.A.) (“Stemtech HealthSciences”)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Canada, Inc. (Canada)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Health Sciences S. de R.L. de C.V. (“Mexico”)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Services SARL de C.V. (Mexico) (“Stemtech Mexico”)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Malaysia Holdings Sdn. Bhd. (“Malaysia”)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Malaysia Sdn. Bhd. (“Malaysia”)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stemtech Taiwan Holding, Inc. (“U.S.A.”)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tecrecel S.A. (“Ecuador”)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Food & Health Tech Foodhealth SA (“Ecuador”)</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The December 31, 2021 consolidated balance sheet included herein was derived from audited consolidated financial statements as of that date. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously filed in its Annual Report on Form 10-K for the year ended December 21, 2021<i>.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38500000	usd
CY2022Q2	STEK	Working Capital Deficiency WorkingCapitalDeficiency	-32400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zXEkwQbhaEcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zw9lrxC4nX2c">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	119771	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	249659	usd
CY2022Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	81356	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	186746	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	201127	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	436405	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	1646941	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	1275375	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	4224585	usd
	STEK	Increase Decrease In Derivative Liabilities Redemptions IncreaseDecreaseInDerivativeLiabilitiesRedemptions	-305944	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	1352932	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-22341116	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	27612689	usd
CY2022Q2	STEK	Proceeds From Factoring Liability ProceedsFromFactoringLiability	241000	usd
CY2022Q2	STEK	Factoring Liability FactoringLiability	217907	usd
CY2018Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	150000	usd
CY2019Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	267000	usd
CY2022Q2	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd
CY2019Q3	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	9800	usd
CY2020Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	10664	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	2500000	usd
CY2022Q2	STEK	Tax Assessment Amount TaxAssessmentAmount	250000	usd

Files In Submission

Name	View Source	Status
0001493152-22-023772-index-headers.html	Edgar Link	pending
0001493152-22-023772-index.html	Edgar Link	pending
0001493152-22-023772.txt	Edgar Link	pending
0001493152-22-023772-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stek-20220630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
stek-20220630_lab.xml	Edgar Link	unprocessable
stek-20220630_pre.xml	Edgar Link	unprocessable
stek-20220630_cal.xml	Edgar Link	unprocessable
stek-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STEK
Stemtech Corp Stock $stek

2022 Q3 Form 10-Q Financial Statement

#000149315222023772 Filed on August 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK Stemtech Corp Stock $stek

2022 Q3 Form 10-Q Financial Statement

#000149315222023772 Filed on August 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK
Stemtech Corp Stock $stek